Scpharmaceuticals Stock Analysis
SCPH Stock | USD 4.04 0.07 1.76% |
Scpharmaceuticals is overvalued with Real Value of 3.59 and Target Price of 15.17. The main objective of Scpharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Scpharmaceuticals is worth, separate from its market price. There are two main types of Scpharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Scpharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Scpharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Scpharmaceuticals | Build AI portfolio with Scpharmaceuticals Stock |
Scpharmaceuticals Stock Analysis Notes
About 77.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.92. Scpharmaceuticals had not issued any dividends in recent years. scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts. SC Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Scpharmaceuticals contact John Tucker at 617 517 0730 or learn more at https://www.scpharmaceuticals.com.Scpharmaceuticals Investment Alerts
Scpharmaceuticals is way too risky over 90 days horizon | |
Scpharmaceuticals appears to be risky and price may revert if volatility continues | |
Scpharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 36.33 M. Net Loss for the year was (85.15 M) with profit before overhead, payroll, taxes, and interest of 28.93 M. | |
Scpharmaceuticals currently holds about 55.85 M in cash with (70.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
Over 77.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: With 42 percent stake, scPharmaceuticals Inc. seems to have captured institutional investors interest |
Scpharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Scpharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
27th of March 2024 Upcoming Quarterly Report | View | |
8th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Scpharmaceuticals Largest EPS Surprises
Earnings surprises can significantly impact Scpharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.4 | -0.44 | -0.04 | 10 | ||
2021-08-11 | 2021-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
2021-05-12 | 2021-03-31 | -0.3 | -0.26 | 0.04 | 13 |
Scpharmaceuticals Stock Institutional Investors
Shares | Velan Capital Investment Management Lp | 2025-03-31 | 917.7 K | Geode Capital Management, Llc | 2025-03-31 | 807.5 K | State Street Corp | 2025-03-31 | 733.7 K | Tejara Capital Ltd | 2025-03-31 | 662.1 K | J. Goldman & Co Lp | 2025-03-31 | 586.2 K | Apis Capital Advisors, Llc | 2025-03-31 | 504.9 K | Perceptive Advisors Llc | 2025-03-31 | 500 K | Thrivent Financial For Lutherans | 2025-03-31 | 383.2 K | Stonepine Capital Management Llc | 2025-03-31 | 347.7 K | Orbimed Advisors, Llc | 2025-03-31 | 6.1 M | Rubric Capital Management Lp | 2025-03-31 | 4.8 M |
Scpharmaceuticals Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 209.58 M.Scpharmaceuticals Profitablity
The company has Profit Margin (PM) of (2.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.51) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.51.Management Efficiency
Scpharmaceuticals has return on total asset (ROA) of (0.492) % which means that it has lost $0.492 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.3402) %, meaning that it created substantial loss on money invested by shareholders. Scpharmaceuticals' management efficiency ratios could be used to measure how well Scpharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Total Assets is estimated to decrease to about 93.4 M. The current Net Tangible Assets is estimated to decrease to about 54.8 MEffective leadership at Scpharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
As of the 4th of July, Scpharmaceuticals has the Risk Adjusted Performance of 0.2061, semi deviation of 4.16, and Coefficient Of Variation of 820.51. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Scpharmaceuticals, as well as the relationship between them.Scpharmaceuticals Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Scpharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Scpharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Scpharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Scpharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Scpharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Scpharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scpharmaceuticals Outstanding Bonds
Scpharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Scpharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Scpharmaceuticals bonds can be classified according to their maturity, which is the date when Scpharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Scpharmaceuticals Predictive Daily Indicators
Scpharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Scpharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Scpharmaceuticals Forecast Models
Scpharmaceuticals' time-series forecasting models are one of many Scpharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Scpharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Scpharmaceuticals Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Scpharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Scpharmaceuticals shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Scpharmaceuticals. By using and applying Scpharmaceuticals Stock analysis, traders can create a robust methodology for identifying Scpharmaceuticals entry and exit points for their positions.
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts. SC Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Current Scpharmaceuticals Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Scpharmaceuticals analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Scpharmaceuticals analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
15.17 | Strong Buy | 6 | Odds |
Most Scpharmaceuticals analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Scpharmaceuticals stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Scpharmaceuticals, talking to its executives and customers, or listening to Scpharmaceuticals conference calls.
Scpharmaceuticals Stock Analysis Indicators
Scpharmaceuticals stock analysis indicators help investors evaluate how Scpharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Scpharmaceuticals shares will generate the highest return on investment. By understating and applying Scpharmaceuticals stock analysis, traders can identify Scpharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 46.8 M | |
Long Term Debt | 51.4 M | |
Common Stock Shares Outstanding | 44.5 M | |
Total Stockholder Equity | 13.3 M | |
Property Plant And Equipment Net | 1.3 M | |
Cash And Short Term Investments | 75.7 M | |
Cash | 75.7 M | |
Accounts Payable | 3.9 M | |
Net Debt | -23 M | |
50 Day M A | 3.3411 | |
Total Current Liabilities | 14.9 M | |
Other Operating Expenses | 101.1 M | |
Non Current Assets Total | 1.7 M | |
Non Currrent Assets Other | 341 K | |
Stock Based Compensation | 5.4 M |
Complementary Tools for Scpharmaceuticals Stock analysis
When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stocks Directory Find actively traded stocks across global markets |